Advertisement

Search Results

Advertisement



Your search for all items matches 26668 pages

Showing 101 - 150


lung cancer

Study Finds Medicaid Expansion May Be Associated With Decrease in Early Lung Cancer Mortality

Medicare expansion under the Affordable Care Act may have improved outcomes for patients with lung cancer, the leading cause of cancer death in the United States, according to data presented at the 2021 ASCO Quality Care Symposium.1 The National Cancer Database analysis of nearly 12,000 patients...

Donations to St. Jude Children’s Research Center Soar; Inspiration4 SpaceX Journey Exceeds $200 Million Goal

On September 15, 2021, SpaceX launched the Inspiration4 mission, sending four civilians on a 3-day trip orbiting the earth. The passengers were the first to travel on an all-civilian space journey in an effort to further scientific and aerospace research while at the same time raise funds for...

genomics/genetics

FDA Recognizes Memorial Sloan Kettering Database of Molecular Tumor Marker Information

On October 7, the U.S. Food and Drug Administration (FDA) granted recognition to a partial listing of the Memorial Sloan Kettering Cancer Center Oncology Knowledge Base (OncoKB) as the first tumor mutation database to be included in the Public Human Genetic Variant Databases.  The FDA recognized a...

covid-19

Resurgence of COVID-19 Infection in a Large Highly Vaccinated U.S. Health System Workforce

In a letter to the editor in The New England Journal of Medicine, Jocelyn Keehner, MD, of the University of California San Diego Health (UCSDH), and colleagues describe a marked resurgence of COVID-19 infections among fully vaccinated workers in the UCSDH workforce in July 2021.1 The resurgence...

neuroendocrine tumors

Second Primary Cancers in Patients With Neuroendocrine Tumors

In a population-based study reported in a research letter in JAMA Oncology, Bateni et al found that 8% of patients with neuroendocrine tumors (NETs) developed second primary cancers over approximately 7.5 years of follow-up, with types of secondary malignancies differing according to NET type. The...

solid tumors
hematologic malignancies
covid-19

Antibody Response to COVID-19 Vaccination in Patients With Hematologic or Solid Cancers

In a study reported in JAMA Oncology, Mair et al found that antibody response to COVID-19 vaccination was poorer in patients with hematologic or solid malignancies compared with health-care workers. The investigators also identified factors associated with poorer antibody response among patients....

issues in oncology
palliative care

Disparities in Terminal Hospitalization Among Adults With Metastatic Cancer

In a retrospective population-based study reported in JAMA Network Open, Deeb et al found that patients with metastatic cancer from racial and ethnic minority groups and those without private insurance were more likely to be admitted from the emergency department, receive invasive mechanical...

hematologic malignancies

Zanubrutinib for Waldenström’s Macroglobulinemia

On August 31, 2021, the Bruton’s tyrosine kinase inhibitor zanubrutinib was approved for treatment of adults with Waldenström’s macroglobulinemia.1 Supporting Efficacy Data Approval was based on findings in patients receiving zanubrutinib in the phase III open-label ASPEN trial (ClinicalTrials.gov...

President Biden Appoints Members to National Cancer Advisory Board

President Biden announced the appointment of seven distinguished clinicians and researchers to the National Cancer Advisory Board, which plays an important role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program. President Biden...

issues in oncology
survivorship

Courtney Williams, DrPH, on Cancer Survivors: Working Together to Improve Patient Adherence

Courtney Williams, DrPH, of the National Cancer Institute, discusses the costs associated with cancer survivors who don’t take their medications and cites the need for research to better understand whether residing in an urban or rural area may affect prescription adherence, and what interventions...

lung cancer
immunotherapy

Jyoti Patel, MD, Offers Thoughts on Maintenance Durvalumab Utilization

Study discussant Jyoti Patel, MD, Medical Director of Thoracic Oncology and Assistant Director for Clinical Research at the Lurie Cancer Center of Northwestern University, Chicago, called the research “important for many reasons.” Although the study analyzed data from both open and closed claims,...

lung cancer
immunotherapy

Maintenance Durvalumab: Increased Utilization May Improve Outcomes in NSCLC

Maintenance durvalumab, the standard-of-care treatment for patients with unresectable stage III non–small cell lung cancer (NSCLC), remains significantly underutilized, according to data presented at the International Association for the Study of Lung Cancer (IASLC) 2021 World Conference on Lung...

lymphoma
immunotherapy

Tackling a Growing Need: Options After CAR T-Cell Therapy for Lymphoma

For aggressive B-cell lymphomas, chimeric antigen receptor (CAR) T-cell therapy saves lives, but relapse remains common, and a second-line standard of care is lacking. During the 2021 Pan Pacific Lymphoma Conference, Grzegorz (Greg) S. Nowakowski, MD, Professor of Medicine and Oncology, Lymphoma...

gynecologic cancers
issues in oncology

Study Examines Benefits of Cervical Cancer Screening Program Tailored to Transgender Men and Nonbinary People

Worldwide, cervical cancer is the fifth most commonly occurring cancer in women, mostly due to human papillomavirus (HPV) infection. In 2020, globally, an estimated 604,237 women were diagnosed with cervical cancer and about 341,843 died from the disease. In the United States, in 2021, it is...

lung cancer
immunotherapy

Black Patients With Advanced NSCLC Receiving Immunotherapy May Have a Lower Risk of Death Than White Patients

Collectively, Black Americans have the highest death rate and shortest survival of any racial/ethnic group in the United States for most cancers; Black men also have the highest cancer incidence rate. Despite improvements in survival disparities between Black and White Americans in specific cancers ...

hepatobiliary cancer

Addition of Ramucirumab or Merestinib to First-Line Chemotherapy in Advanced Biliary Tract Cancer

In a phase II trial reported in The Lancet Oncology, Juan W. Valle, MD, and colleagues found that no progression-free survival benefit was achieved with the addition of either the VEGFR2 inhibitor ramucirumab or the MEK inhibitor merestinib to first-line cisplatin/gemcitabine chemotherapy in...

head and neck cancer
cns cancers

Factors Associated With Risk of Hearing Loss in Pediatric Patients Receiving Radiation and Chemotherapy

In a single-institution cohort study reported in the Journal of Clinical Oncology, Keilty et al identified factors associated with an increased risk of hearing loss in pediatric patients receiving radiation therapy and chemotherapy for central nervous system and head and neck tumors. The study...

issues in oncology

Benjamin W. Corn, MD, on Integrating Hope Into Clinical Oncology

Benjamin W. Corn, MD, of Shaare Zedek Medical Center in Jerusalem, discusses hope: what it takes for hope to thrive; how he and his colleagues are helping patients and providers become more hopeful through workshops; and his collaboration with the Southwest Oncology Group to aid patients, through...

Emily K. Bergsland, MD: Specializing in Neuroendocrine Tumors, With a Broad Focus on Collaborative Research

Gastrointestinal oncologist Emily K. Bergsland, MD, was born and spent her formative years in La Crosse, Wisconsin, situated on the banks of the Mississippi River. “No one in my family was in the medical field; however, both my parents valued higher education. In fact, when I was in high school, my ...

prostate cancer

Adding Value to Clinical Decision-Making in Nonmetastatic Castration-Resistant Prostate Cancer

Several recent investigations have led to the U.S. Food and Drug Administration (FDA) approval of novel antiandrogens to treat nonmetastatic castration-resistant prostate cancer. Yet, this work has not addressed the treatment of nonmetastatic hormone-sensitive biochemically recurrent prostate...

lymphoma

DA-EPOCH-R for Children and Adolescents With Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

In a phase II trial reported in the Journal of Clinical Oncology, Burke et al found that dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab (DA-EPOCH-R) did not improve event-free survival vs historical controls in children and adolescents with ...

geriatric oncology
symptom management

Effect of Geriatric Assessment–Driven Intervention on Incidence of Severe Chemotherapy-Related Toxicity in Older Patients With Cancer

In a single-center study reported in JAMA Oncology, Daneng Li, MD, and colleagues found that a geriatric assessment–driven intervention (GAIN) was associated with a reduced incidence of grade ≥ 3 adverse events and a higher frequency of completion of advance directives vs standard of care among...

kidney cancer
immunotherapy

Rates of Postprotocol Immunotherapy Use in Patients Enrolled in Kidney Cancer Clinical Trials

In an analysis reported in JAMA Network Open, Sharp et al identified the frequency of use of postprotocol PD-1/PD-L1 inhibitors in control group patients receiving the tyrosine kinase inhibitor sunitinib in randomized trials comparing PD-1/PD-L1 inhibitor–containing combination therapy vs sunitinib ...

colorectal cancer

Does a Longer Interval Before Surgery Among Patients With Locally Advanced Rectal Cancer Lead to Worse Survival?

In an Italian retrospective cohort study reported in JAMA Surgery, Deidda et al found that a longer vs shorter delay to surgery among patients with locally advanced rectal cancer with minor or no pathologic response to neoadjuvant chemoradiotherapy was associated with significantly poorer overall...

lung cancer
immunotherapy

Adjuvant Atezolizumab Following Adjuvant Chemotherapy for Resected Stage IB to IIIA NSCLC

In the phase III IMpower010 trial reported in The Lancet, Enriqueta Felip, MD, and colleagues found that the use of adjuvant atezolizumab after adjuvant platinum-based chemotherapy significantly improved disease-free survival vs best supportive care in patients with resected stage II to IIIA...

colorectal cancer
genomics/genetics

Jenny F. Seligmann, MBChB, PhD, on Colorectal Cancer: Adavosertib Compared With Active Monitoring

Jenny F. Seligmann, MBChB, PhD, of the University of Leeds, discusses phase II findings that suggest adavosertib improved progression-free survival, compared with active monitoring, by inhibiting the WEE1 kinase in patients with RAS- and TP53-mutant metastatic colorectal cancer. In the trial,...

hematologic malignancies
leukemia
immunotherapy
global cancer care

A Look at Tomorrow’s CAR T-Cell Therapy Today

Some of the most impressive data on chimeric antigen receptor (CAR) T-cell therapy have come from studies conducted in China. Attendees at the 2021 Pan Pacific Lymphoma Conference heard from one of the leading Chinese investigators, Peihua (Peggy) Lu, MD, of Lu Daopei Hospital, who described the...

breast cancer
issues in oncology

Factors Associated With Early Discontinuation of Endocrine Therapy for Ductal Carcinoma in Situ

In an analysis from the NRG Oncology/NSABP B-35 trial reported in the Journal of Clinical Oncology, N. Lynn Henry, MD, PhD, and colleagues identified toxicity and patient-reported outcome factors associated with early discontinuation of adjuvant endocrine therapy in women with ductal carcinoma in...

gynecologic cancers

Trends in Use of Neoadjuvant Chemotherapy and Association With Overall Survival in Patients With Advanced Ovarian Cancer

In a study reported in JAMA Oncology, Alexander Melamed, MD, MPH, and colleagues found that improvements in median overall survival have been similar in patients from U.S. cancer programs that did vs did not increase their use of neoadjuvant chemotherapy for women with advanced ovarian cancer in...

lymphoma
immunotherapy

Axicabtagene Ciloleucel for Adult Patients With Primary Mediastinal B-Cell Lymphoma: Real-World Outcomes

In a retrospective cohort study reported in a research letter in Blood Advances, Jennifer L. Crombie, MD, and colleagues found that axicabtagene ciloleucel produced high overall and complete response rates in patients with primary mediastinal B-cell lymphoma. They also observed some evidence to...

leukemia
immunotherapy

FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor ALL

On October 1, the U.S. Food and Drug Administration (FDA) approved brexucabtagene autoleucel (Tecartus), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ZUMA-3 Efficacy was evaluated ...

issues in oncology
cost of care
lung cancer
gynecologic cancers

Two Studies Show Health-Care Costs May Impact Follow-up Care After Cancer Screening

Eleven years ago this month, the scans and exams that hold the most power to spot the early signs of cancer became available for free to many American adults through the passing of the Affordable Care Act. Now, two new studies show that when those screening tests reveal potentially troubling signs, ...

prostate cancer

Characteristics of and Outcomes in Luminal and Basal Subtypes of Metastatic Castration-Resistant Prostate Cancer

In a retrospective cohort study reported in JAMA Oncology, Aggarwal et al found that metastatic castration-resistant prostate cancer could be categorized into luminal and basal subtypes, and that androgen-signaling inhibitor treatment was associated with better outcomes in patients diagnosed with...

issues in oncology

Improved Health Insurance Coverage, Access to Care May Lessen Racial/Ethnic Disparities in Childhood Cancer Survival

A new study published by Jingxuan Zhao, MPH, and colleagues in Cancer Epidemiology, Biomarkers & Prevention found racial/ethnic disparities in survival among newly diagnosed patients with childhood cancers in the United States, and that area-level socioeconomic status and health insurance...

colorectal cancer

Radioembolization Plus Second-Line Chemotherapy for Colorectal Liver Metastases

In the phase III EPOCH trial reported in the Journal of Clinical Oncology, Mary F. Mulcahy, MD, and colleagues found that the addition of transarterial yttrium-90 radioembolization (TARE) to second-line chemotherapy significantly prolonged progression-free survival and hepatic progression–free...

hepatobiliary cancer
genomics/genetics

Ivosidenib vs Placebo for Previously Treated Advanced IDH1-Mutated Cholangiocarcinoma: Final Overall Survival Analysis of the ClarIDHy Trial

As reported in JAMA Oncology by Andrew X. Zhu, MD, PhD, and colleagues, the final overall survival analysis of the pivotal phase III ClarIDHy trial showed prolonged overall survival with ivosidenib vs placebo in previously treated patients with unresectable or metastatic cholangiocarcinoma and an...

colorectal cancer
genomics/genetics

Addition of Panitumumab to Fluorouracil/Leucovorin as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer

In the German phase II PANAMA trial reported in the Journal of Clinical Oncology, Modest et al found that the addition of the monoclonal antibody panitumumab to fluorouracil (5-FU)/leucovorin maintenance therapy improved progression-free survival in patients with RAS wild-type metastatic colorectal ...

leukemia

Luis E. Aguirre, MD, on Chronic Myelomonocytic Leukemia: Keys to Assessment and Treatment

Luis E. Aguirre, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses the subset of patients with chronic myelomonocytic leukemia who have a more indolent disease course. Features at diagnosis may include higher hemoglobin and platelet counts or JAK2, SF3B1, and IDH2 mutations; ...

lymphoma

Kieron M. Dunleavy, MD: Update on Primary Mediastinal B-Cell Lymphoma

Kieron M. Dunleavy, MD, of Georgetown University, offers insights into the latest data on treating patients with primary mediastinal B-cell lymphoma: the optimal regimen; whether radiotherapy or stem cell transplants are needed; new information on the biology of the disease; novel agents such as...

gynecologic cancers

Biomarker May Help to Predict Response to Gemcitabine for Patients With High-Grade Serous Ovarian Cancer

For more than 2 decades, the chemotherapy agent gemcitabine has been a mainstay treatment for several types of cancer. Now, scientists have uncovered genetic evidence of which patients with high-grade serous ovarian cancer are likely to benefit from the drug. In a study published by Panagiotis...

leukemia

Study Finds Genetic Predisposition to Higher Lymphocyte Production May Lead to Higher ALL Risk

Research published by Kachuri et al in the American Journal of Human Genetics reveals that children born with a genetic predisposition to produce more lymphocytes—particularly in relation to other types of white blood cells—may be at a higher risk of developing acute lymphoblastic leukemia (ALL)....

covid-19

Effectiveness of mRNA COVID-19 Vaccination in Preventing Symptomatic Infection in Health-Care Personnel

As reported in The New England Journal of Medicine by Pilishvili et al for the Vaccine Effectiveness among Healthcare Personnel Study Team, a case-control study has shown that full vaccination with the COVID-19 mRNA vaccines was highly effective in preventing symptomatic COVID-19 infection in U.S....

colorectal cancer
genomics/genetics

Adavosertib for Patients With TP53- and RAS-Mutant Metastatic Colorectal Cancer

As reported in the Journal of Clinical Oncology by Seligmann et al, the phase II FOCUS4-C trial has shown activity of the WEE1 kinase inhibitor adavosertib in patients with TP53- and RAS-mutant metastatic colorectal cancer with disease control after first-line chemotherapy. As state by the...

immunotherapy

Liver Biopsy for Evaluation of Hepatitis Associated With Immunotherapy

In a retrospective cohort study reported in a research letter in JAMA Oncology, Li et al found that the performance of liver biopsy in patients with grade ≥ 3 alanine aminotransferase (ALT) elevations during immune checkpoint inhibitor therapy was associated with a delayed start of corticosteroid...

multiple myeloma

Triplet Therapy and Lenalidomide Maintenance to Prevent Disease Progression in High-Risk Smoldering Myeloma

In a single-center phase II trial reported in JAMA Oncology, Kazandjian et al found that triplet therapy with carfilzomib, lenalidomide, and dexamethasone (KRd), followed by lenalidomide maintenance, produced high rates of measurable residual disease (MRD)-negative complete response and freedom...

issues in oncology

Sarah S. Mougalian, MD, on a Next-Day Access Program for Patients With Cancer

Sarah S. Mougalian, MD, of Yale Cancer Center, discusses the increasingly common problem of long wait times for access to oncology care. Her team developed a next-day access program in several of Yale’s oncology services, which was well received by patients and decreased the time to first visit.

lung cancer
health-care policy
legislation

Leticia Nogueira, PhD, MPH, on the Association of Medicaid Expansion and Early Mortality Following Lung Cancer Surgery

Leticia Nogueira, PhD, MPH, of the American Cancer Society, discusses results from a study designed to evaluate the impact of Medicaid expansion under the Affordable Care Act (ACA). In Medicaid-expansion states, mortality among patients after lung cancer surgery decreased from 2.4% before the ACA...

issues in oncology
global cancer care

International Survey on Access to Cancer Medicines Considered Essential by Oncologists

An international cross-sectional survey reported in The Lancet Oncology by Fundytus et al found that access to cancer medicines considered essential by oncologists is lacking across the spectrum of low- and lower middle–income to high-income countries.   As stated by the investigators, “The World...

colorectal cancer
genomics/genetics

FDA Expands Cetuximab Label With Combination of Encorafenib for Pretreated BRAF V600E Mutation–Positive Metastatic Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has granted approval of a new indication for cetuximab (Erbitux) in combination with encorafenib (Braftovi) for the treatment of adult patients with metastatic colorectal cancer and a BRAF V600E mutation, as detected by an FDA-approved test, after prior...

breast cancer

Is MRI Cost-Effective for Detecting Cancer in Women With Very Dense Breasts?

A new paper published by Geuzinge et al in the Journal of the National Cancer Institute indicates that adding magnetic resonance imaging (MRI) scans to mammography is cost-effective for detecting breast cancer in women with very dense breasts. About 10% of women have extremely dense breasts, and...

Advertisement

Advertisement



Advertisement